Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS)

Thomas Kuczmarski, Elijah W. Stommel, Kristen Riley, Rup Tandan, Vinay Chaudhry, Lora Clawson, Tracie A. Caller, Patricia L. Henegan, Dominic N. Facciponte, Walter G Bradley, Angeline S. Andrew

Research output: Contribution to journalArticle

Abstract

A recent population-based analysis demonstrated lower risk of the lethal degenerative neuromuscular disease, amyotrophic lateral sclerosis (ALS) associated with history of the use of ‘antineoplastic agents’ and ‘immunosuppressants’. To see if this finding was generalizable to other ALS cohorts, we examined associations between use of these agents and ALS risk in an independent case–control study of n = 414 ALS patients and n = 361 controls in an Eastern US population. Controls were sampled from the general population and among non-neurodegenerative disease patients. A history of chemotherapy treatment was significantly associated with a decreased ALS risk (OR 0.46, 95% CI 0.22–0.89, P = 0.026). We did not observe an association between risk of ALS and immunosuppressant therapy use (OR 0.78, 95% CI 0.50–1.02, P = 0.23). Analyses were adjusted for age, gender, and smoking. Our results support the prior report for chemotherapy treatment and lead to further discussion of the underlying mechanism.

Original languageEnglish (US)
Pages (from-to)1763-1767
Number of pages5
JournalJournal of Neurology
Volume264
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Amyotrophic Lateral Sclerosis
Immunosuppressive Agents
Drug Therapy
Pharmaceutical Preparations
Therapeutics
Population
Neuromuscular Diseases
Antineoplastic Agents
Smoking

Keywords

  • Amyotrophic lateral sclerosis
  • Case–control
  • Chemotherapy
  • Immunosuppressant
  • Neurodegenerative

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Kuczmarski, T., Stommel, E. W., Riley, K., Tandan, R., Chaudhry, V., Clawson, L., ... Andrew, A. S. (2017). Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS). Journal of Neurology, 264(8), 1763-1767. https://doi.org/10.1007/s00415-017-8564-2

Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS). / Kuczmarski, Thomas; Stommel, Elijah W.; Riley, Kristen; Tandan, Rup; Chaudhry, Vinay; Clawson, Lora; Caller, Tracie A.; Henegan, Patricia L.; Facciponte, Dominic N.; Bradley, Walter G; Andrew, Angeline S.

In: Journal of Neurology, Vol. 264, No. 8, 01.08.2017, p. 1763-1767.

Research output: Contribution to journalArticle

Kuczmarski, T, Stommel, EW, Riley, K, Tandan, R, Chaudhry, V, Clawson, L, Caller, TA, Henegan, PL, Facciponte, DN, Bradley, WG & Andrew, AS 2017, 'Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS)', Journal of Neurology, vol. 264, no. 8, pp. 1763-1767. https://doi.org/10.1007/s00415-017-8564-2
Kuczmarski, Thomas ; Stommel, Elijah W. ; Riley, Kristen ; Tandan, Rup ; Chaudhry, Vinay ; Clawson, Lora ; Caller, Tracie A. ; Henegan, Patricia L. ; Facciponte, Dominic N. ; Bradley, Walter G ; Andrew, Angeline S. / Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS). In: Journal of Neurology. 2017 ; Vol. 264, No. 8. pp. 1763-1767.
@article{c15a7bf83c4d4be89b660ef43ce3fd70,
title = "Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS)",
abstract = "A recent population-based analysis demonstrated lower risk of the lethal degenerative neuromuscular disease, amyotrophic lateral sclerosis (ALS) associated with history of the use of ‘antineoplastic agents’ and ‘immunosuppressants’. To see if this finding was generalizable to other ALS cohorts, we examined associations between use of these agents and ALS risk in an independent case–control study of n = 414 ALS patients and n = 361 controls in an Eastern US population. Controls were sampled from the general population and among non-neurodegenerative disease patients. A history of chemotherapy treatment was significantly associated with a decreased ALS risk (OR 0.46, 95{\%} CI 0.22–0.89, P = 0.026). We did not observe an association between risk of ALS and immunosuppressant therapy use (OR 0.78, 95{\%} CI 0.50–1.02, P = 0.23). Analyses were adjusted for age, gender, and smoking. Our results support the prior report for chemotherapy treatment and lead to further discussion of the underlying mechanism.",
keywords = "Amyotrophic lateral sclerosis, Case–control, Chemotherapy, Immunosuppressant, Neurodegenerative",
author = "Thomas Kuczmarski and Stommel, {Elijah W.} and Kristen Riley and Rup Tandan and Vinay Chaudhry and Lora Clawson and Caller, {Tracie A.} and Henegan, {Patricia L.} and Facciponte, {Dominic N.} and Bradley, {Walter G} and Andrew, {Angeline S.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1007/s00415-017-8564-2",
language = "English (US)",
volume = "264",
pages = "1763--1767",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "D. Steinkopff-Verlag",
number = "8",

}

TY - JOUR

T1 - Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS)

AU - Kuczmarski, Thomas

AU - Stommel, Elijah W.

AU - Riley, Kristen

AU - Tandan, Rup

AU - Chaudhry, Vinay

AU - Clawson, Lora

AU - Caller, Tracie A.

AU - Henegan, Patricia L.

AU - Facciponte, Dominic N.

AU - Bradley, Walter G

AU - Andrew, Angeline S.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - A recent population-based analysis demonstrated lower risk of the lethal degenerative neuromuscular disease, amyotrophic lateral sclerosis (ALS) associated with history of the use of ‘antineoplastic agents’ and ‘immunosuppressants’. To see if this finding was generalizable to other ALS cohorts, we examined associations between use of these agents and ALS risk in an independent case–control study of n = 414 ALS patients and n = 361 controls in an Eastern US population. Controls were sampled from the general population and among non-neurodegenerative disease patients. A history of chemotherapy treatment was significantly associated with a decreased ALS risk (OR 0.46, 95% CI 0.22–0.89, P = 0.026). We did not observe an association between risk of ALS and immunosuppressant therapy use (OR 0.78, 95% CI 0.50–1.02, P = 0.23). Analyses were adjusted for age, gender, and smoking. Our results support the prior report for chemotherapy treatment and lead to further discussion of the underlying mechanism.

AB - A recent population-based analysis demonstrated lower risk of the lethal degenerative neuromuscular disease, amyotrophic lateral sclerosis (ALS) associated with history of the use of ‘antineoplastic agents’ and ‘immunosuppressants’. To see if this finding was generalizable to other ALS cohorts, we examined associations between use of these agents and ALS risk in an independent case–control study of n = 414 ALS patients and n = 361 controls in an Eastern US population. Controls were sampled from the general population and among non-neurodegenerative disease patients. A history of chemotherapy treatment was significantly associated with a decreased ALS risk (OR 0.46, 95% CI 0.22–0.89, P = 0.026). We did not observe an association between risk of ALS and immunosuppressant therapy use (OR 0.78, 95% CI 0.50–1.02, P = 0.23). Analyses were adjusted for age, gender, and smoking. Our results support the prior report for chemotherapy treatment and lead to further discussion of the underlying mechanism.

KW - Amyotrophic lateral sclerosis

KW - Case–control

KW - Chemotherapy

KW - Immunosuppressant

KW - Neurodegenerative

UR - http://www.scopus.com/inward/record.url?scp=85023741445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023741445&partnerID=8YFLogxK

U2 - 10.1007/s00415-017-8564-2

DO - 10.1007/s00415-017-8564-2

M3 - Article

C2 - 28711998

AN - SCOPUS:85023741445

VL - 264

SP - 1763

EP - 1767

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 8

ER -